Panelists explored responsible, patient-centered use of artificial intelligence (AI) in cardiovascular care at the American ...

While a bigger paycheck is more than welcome (especially in the Garden State), it’s the perks that matter most to workers.

Nearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million in a lawsuit alleging that ...

J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...

Dr. Reddy’s Laboratories RDY and China-based Bio-Thera Solutions announced that they have entered into commercialization and license agreements for BAT2206, a proposed biosimilar of Johnson & ...

Pictet Asset Management boosted its Johnson & Johnson holdings by 12.3%, adding over 155,000 shares in Q4. This raised its ...

U.S. stock indices slump amid tariff talks while healthcare sees major developments: J&J faces a $1.6B lawsuit, new FDA approvals, and a $2B ...

Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D ...

Javerbaum Wurgaft Hicks Kahn Wikstrom & Sinins hired a retired New Jersey Superior Court judge,and more moves.

A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64B after a jury found it liable in a ...

Despite the public uproar over some controversial policies and pressures to keep a low profile, a number of business leaders ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...